The Effect of Beta-glucan in Non-Small Cell Lung Cancer

Recruiting · NCT00682032 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Louisville

Interventions studied

beta-glucan

The purpose of this study is to determine how beta-glucan affects the immune system in subjects with non-small cell lung cancer.

Age range

18 Years and older

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Not applicable (e.g. observational or device study)

Study type

Interventional (participants receive a specific treatment)

history of hypersensitivity reactions attributed to beta-glucan
currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy
presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
AIM 3:
Inclusion Criteria:
resectable non-small cell lung cancer (NSCLC), as determined by a thoracic surgeon
treatment naive
able to swallow pills
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
must be an operative candidate
absolute neutrophil count (ANC) at least 1500/microl
able to understand and willing to sign a written informed consent document
Exclusion Criteria:
history of hypersensitivity reactions attributed to beta-glucan
currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy
presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

1 location listed across 1 US state.